Author:
Vogelmeier Claus F., ,Gaga Mina,Aalamian-Mattheis Maryam,Greulich Timm,Marin Jose M.,Castellani Walter,Ninane Vincent,Lane Stephen,Nunez Xavier,Patalano Francesco,Clemens Andreas,Kostikas Konstantinos
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from www.goldcopd.org . Accessed on 4 May 2017
2. Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20:46–53.
3. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51–60.
4. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222–34.
5. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454–63.
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献